NCT05385783View on ClinicalTrials.gov

A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

August 2, 2022

Primary Completion Date

October 16, 2023

Study Completion Date

January 18, 2024

Conditions
Major Depressive Disorder
Interventions
DRUG

CYB003

CYB003 is a synthetic psilocybin analog.

BEHAVIORAL

Psychotherapy

Manualized psychotherapy (called EMBARK) performed by facilitators

DRUG

Placebo

Placebo

BEHAVIORAL

Psychological Support

Manualized psychological support performed by facilitators

Trial Locations (3)

30030

iResearch Atlanta, Decatur

30331

CenExel ACMR, Atlanta

07724

Clinilabs Drug Development Corporation, Eatontown

All Listed Sponsors
collaborator

Clinilabs Drug Development Corporation

UNKNOWN

collaborator

Drug Safety Navigator

UNKNOWN

lead

Cybin IRL Limited

INDUSTRY